New Treatment for Glioblastoma Multiforme Developed

New Treatment for Glioblastoma Multiforme Developed by NFCR Scientists

Dr. Web Cavenee and Dr. Paul Fisher Publish Report Titled “Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin”

NFCR congratulates Dr. Web Cavenee and Dr. Paul B. Fisher on their discovery of a new pharmacological agent to treat glioblastoma multiforme (GBM), the deadliest brain cancer, which they have been developing together with NFCR support.

This new pharmacological agent could – with additional chemistry – lead to a new drug to prevent radiation-induced invasion of GBM cells. The researchers have tested their pharmacological agent in combination with radiation with profound survival benefits in pre-clinical models. Click here to read the full report by the scientists.

Paul B. Fisher, M.Ph., Ph.D., Director of the Virginia Commonwealth University’s (VCU) Institute of Molecular Medicine (VIMM), focuses on cancer genetics and Web Cavenee Ph.D., Director of the Ludwig Institute for Cancer Research at the University of California at San Diego focuses on GBM. An exciting breakthrough for the treatment of GBM, this is about collaboration between two scientists on opposite coasts and shows how NFCR research may lead to tangible therapies for multiple cancers.

NFCR has been funding Dr. Fisher’s research since 2008, and Dr. Cavenee’s research starting in 2002. “NFCR scientists are making headway in the fight against one of the most aggressive form of cancer, GBM, by working together on vital pre-clinical models,” said Franklin C. Salisbury, Jr., NFCR CEO. “For years, discoveries from NFCR-funded research have led to better treatments today – and this latest discovery by two incredibly talented scientists gives us proof there will be improved therapies for GBM and multiple cancers in the foreseeable future.”

About the Scientists

Dr. Paul B. Fisher, M.Ph., Ph.D. is the Director of the VCU Institute of Molecular Medicine at the VCU School of Medicine and is a professor and Chair of Human and Molecular Genetics at the VCU School of Medicine. Dr. Fisher’s laboratory focuses on understanding the molecular and biochemical basis of cancer etiology and progression with an emphasis on translating this information to develop improved methods for diagnosing, staging and treating cancer. Read more about Dr. Fisher on NFCR’s scientist page and VCU’s website. Dr. Fisher was the Virginia Outstanding Scientist of the Year in 2014.

Dr. Web Cavenee, Ph.D., formerly an NFCR-funded research Fellow and Director of the Ludwig Institute for Cancer Research (LICR) at UCSD, is now Chairman of NFCR’s Scientific Advisory Board and Director of Strategic Alliances, Central Nervous System Tumors at LICR UCSD. His pioneering research has led to groundbreaking discoveries that have fundamentally changed our understanding of the molecular mechanisms that drive the growth, migration, and survival of glioblastoma multiforme cells—leading to potential new therapeutic approaches for treating GBM. Dr. Cavenee was recently awarded the 2016 Feldman Founder’s Award for Adult Brain Tumor Research from the National Brain Tumor Society. Read more about Dr. Cavenee and the NFCR’s Scientific Advisory Board.

Comments(13)

REPLY
Susan says
January 5, 2017 at 4:41 am

Is this trial available in australia , r we able to come to u
REPLY
Tina Pare says
June 20, 2017 at 1:47 pm

Is this available in Massachusetts
REPLY
Jerry Musgrove says
June 22, 2017 at 5:47 pm

is this available in texas
REPLY
CJ FRAME says
August 12, 2017 at 12:15 am

We live here in Southern California. How do I go about getting my sister enrolled?
REPLY
Kathy mullen says
September 21, 2017 at 11:34 am

Is this trial available in Minnesota
REPLY
Mary Sheahan says
September 27, 2017 at 1:09 pm

Is this something which my can be of benefit to my husband who is presently undergoing standard treatment for newly diagnosed gliomablasta multiforme?
REPLY
Ana Aitawa says
November 17, 2017 at 5:47 am

Global Glioblastoma multiforme drugs market by drug types (Bevacizumab, Temozolomide, Carmustine) to reach nearly $890 Million in 2021, at a CAGR of 13.4% from 2017 to 2021 – iHealthcareAnalyst, Inc.
https://www.ihealthcareanalyst.com/report/glioblastoma-multiforme-drugs-market/
REPLY
Valerie Haver says
November 30, 2017 at 1:01 pm

Are you looking for patients to try the drug. 62 year old female diagnosed mid Sept, 2017.
REPLY
Santosh says
December 18, 2017 at 12:08 am

Will this be available in Asia ?? Please share any available information. Thanks
REPLY
Kali says
January 19, 2018 at 12:04 am

Hello! I’m at work browsing your blog from my new iphone 4!
Just wanted to say I love reading through your blog
and look forward to all yor posts! Keep up the excellent work!
REPLY
Gerald Wiebeck says
April 11, 2018 at 12:39 pm

Hello:

Could you please help me by forwarding my email to researchers looking into the hereditary gene issues connected to GBM?

According to statistics only 2 to 3 people out of 100,000 ever get GBM. How can that be!? Since I don’t know 1,000 people but I do know 4 people who had GBM and died from it.

I personally know four people and I’m related to two of them who were born and raised in Southeast Michigan and died from GBM. One of them died on Valentine’s Day of 2018.

Thank you,

Gerald Wiebeck
REPLY
Billie says
May 25, 2018 at 11:54 pm

Live in Butler, Missouri. Is this available here?
REPLY
Kevin Stoddart says
January 16, 2019 at 2:34 pm

My Dad has just been diagnosed with GMB and I’d love to know if this available – we live in the uk